Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside
Tagit, Oya
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside - Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 - 1 electronic resource (296 p.)
Open Access
Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations.
Creative Commons
English
books978-3-0365-4489-2 9783036544908 9783036544892
10.3390/books978-3-0365-4489-2 doi
Technology: general issues
History of engineering & technology
Materials science
poly(lactic-co-glycolic acid) (PLGA) blood-brain barrier (BBB) current Good Manufacturing Practice (cGMP) Food and Drug Administration (FDA) nanotechnology PLGA nanoparticles neurodegenerative diseases drug delivery central nervous system neuroprotective drugs fluorescent labeling DiI coumarin 6 rhodamine 123 Cy5.5 quantum yield brightness stability of fluorescent label confocal microscopy intracellular internalization in vivo neuroimaging double-emulsion method dry powder inhalation antigen release porous PLGA particles microfluidics methotrexate chitosan PLA/PLGA sustained release micro-implant animal model minimally invasive drug delivery system nanoparticles poly (lactic-co-glycolic acid) (PLGA) microfluidic pharmacokinetics (PK) and biodistribution atorvastatin calcium poly(lactide-co-glycolide) polymeric nanoparticles carrageenan induced inflammation anti-inflammatory radiolabeled nanoparticles nuclear medicine photothermal therapy phthalocyanine SKOVip-kat Katushka TurboFP635 JO-4 PLGA orthotopic tumors 3D culture spheroids poly(lactic-co-glycolic acid) nanomedicine scale-up manufacturing clinical translation inline sonication tangential flow filtration lyophilization downstream processing H. pylori design of experiments poly(lactic-co-glycolic) acid size cancer chemoimmunotherapy immunogenic cell death immune checkpoint blockade PNA5 glycopeptide mas receptor angiotensin PLGA diblock copolymer ester and acid-end capped double emulsion solvent evaporation biocompatible biodegradable cardiovascular nanoparticle solid-state characterization in vitro drug release kinetics modeling PEGylation amine emulsion polyvinyl alcohol (PVA) Pluronic triblock copolymer trehalose sucrose Indomethacin solvents stabilizers morphology particle-size encapsulation drug release cytotoxicity
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside - Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 - 1 electronic resource (296 p.)
Open Access
Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations.
Creative Commons
English
books978-3-0365-4489-2 9783036544908 9783036544892
10.3390/books978-3-0365-4489-2 doi
Technology: general issues
History of engineering & technology
Materials science
poly(lactic-co-glycolic acid) (PLGA) blood-brain barrier (BBB) current Good Manufacturing Practice (cGMP) Food and Drug Administration (FDA) nanotechnology PLGA nanoparticles neurodegenerative diseases drug delivery central nervous system neuroprotective drugs fluorescent labeling DiI coumarin 6 rhodamine 123 Cy5.5 quantum yield brightness stability of fluorescent label confocal microscopy intracellular internalization in vivo neuroimaging double-emulsion method dry powder inhalation antigen release porous PLGA particles microfluidics methotrexate chitosan PLA/PLGA sustained release micro-implant animal model minimally invasive drug delivery system nanoparticles poly (lactic-co-glycolic acid) (PLGA) microfluidic pharmacokinetics (PK) and biodistribution atorvastatin calcium poly(lactide-co-glycolide) polymeric nanoparticles carrageenan induced inflammation anti-inflammatory radiolabeled nanoparticles nuclear medicine photothermal therapy phthalocyanine SKOVip-kat Katushka TurboFP635 JO-4 PLGA orthotopic tumors 3D culture spheroids poly(lactic-co-glycolic acid) nanomedicine scale-up manufacturing clinical translation inline sonication tangential flow filtration lyophilization downstream processing H. pylori design of experiments poly(lactic-co-glycolic) acid size cancer chemoimmunotherapy immunogenic cell death immune checkpoint blockade PNA5 glycopeptide mas receptor angiotensin PLGA diblock copolymer ester and acid-end capped double emulsion solvent evaporation biocompatible biodegradable cardiovascular nanoparticle solid-state characterization in vitro drug release kinetics modeling PEGylation amine emulsion polyvinyl alcohol (PVA) Pluronic triblock copolymer trehalose sucrose Indomethacin solvents stabilizers morphology particle-size encapsulation drug release cytotoxicity